Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Establishment Labs Holdings Inc. has received a consensus rating of "Moderate Buy" from five brokerages, with one hold and four buy ratings.
• The average 12-month target price for Establishment Labs is $55.80, reflecting positive sentiment from analysts despite recent mixed performance.
• In its latest earnings report, the company missed EPS estimates, reporting a loss of ($0.57), but experienced a 16.1% increase in revenue year-over-year, totaling $51.30 million.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $56.50.

A number of research firms recently commented on ESTA. Citigroup lifted their target price on shares of Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Needham & Company LLC reiterated a "buy" rating and set a $48.00 price objective on shares of Establishment Labs in a research note on Friday, June 13th. Mizuho upped their target price on Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. BTIG Research began coverage on Establishment Labs in a research note on Friday, May 16th. They issued a "buy" rating and a $62.00 target price for the company. Finally, Wall Street Zen downgraded Establishment Labs from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Elevation Point Wealth Partners LLC purchased a new position in Establishment Labs during the 1st quarter worth approximately $207,000. New York State Common Retirement Fund acquired a new stake in shares of Establishment Labs in the first quarter worth $894,000. Northern Trust Corp raised its holdings in shares of Establishment Labs by 53.9% during the fourth quarter. Northern Trust Corp now owns 28,165 shares of the company's stock worth $1,298,000 after purchasing an additional 9,865 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Establishment Labs by 15.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock valued at $2,196,000 after purchasing an additional 6,307 shares during the period. Finally, Vestal Point Capital LP boosted its holdings in Establishment Labs by 650.0% in the fourth quarter. Vestal Point Capital LP now owns 300,000 shares of the company's stock valued at $13,821,000 after purchasing an additional 260,000 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Stock Up 2.3%

NASDAQ:ESTA traded up $0.91 during mid-day trading on Friday, hitting $40.00. 361,226 shares of the company's stock traded hands, compared to its average volume of 487,587. The company has a fifty day moving average of $40.82 and a 200 day moving average of $37.24. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. Establishment Labs has a twelve month low of $26.56 and a twelve month high of $50.85. The company has a market capitalization of $1.16 billion, a P/E ratio of -13.11 and a beta of 0.83.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The business had revenue of $51.30 million for the quarter, compared to analysts' expectations of $50.80 million. During the same quarter in the previous year, the firm posted ($0.62) EPS. Establishment Labs's revenue was up 16.1% on a year-over-year basis. Establishment Labs has set its FY 2025 guidance at EPS. On average, analysts forecast that Establishment Labs will post -2.41 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.